SIRT1在胃癌组织中表达及对患者预后的影响  

Expressions of SIRT1 as prognostic biomarker on resectable gastric cancer patient

作　　者：丁竞竞[1] 何松[2] 张建兵[2] 吴徐明[2] 陈颜夙[1] 夏晓伟[1] 王守宇[1] 强福林[2] 周建伟[1] 

机构地区：[1]南京医科大学公共卫生学院分子毒理实验室,江苏南京210029 [2]南通市肿瘤医院病理科,江苏南通226361

出　　处：《南京医科大学学报（自然科学版）》2011年第8期1142-1147,共6页Journal of Nanjing Medical University(Natural Sciences)

基　　金：国家自然科学基金重点项目资助(30930080)

摘　　要：目的:探讨胃癌和癌旁组织中SIRT1的表达及其对患者预后的影响。方法:收集1990年1月至1995年12月142例胃癌单纯手术治疗患者的临床病理资料,术后生存随访资料,将癌组织与相对应癌旁组织制作组织芯片,通过免疫组化的方法,分别获得SIRT1在其中的表达评分。分析SIRT1表达与患者临床病理指标及预后之间的关系。结果:本研究最终获得113例患者的有效信息,SIRT1在113例胃癌组织中的表达显著低于癌旁组织,差异具有统计学意义(P<0.05),癌组织中SIRT1低表达患者癌体浸润深度、淋巴结转移比例、远处转移比例均显著高于高表达患者(P<0.05),pTNM分期晚期比例也高于高表达患者(P<0.05)。胃癌组织中SIRT1表达越高患者预后越好(HR=0.211,95%CI:0.124～0.360,P<0.001)。结论:胃癌组织中SIRT1表达水平与恶性表型呈负性关系,可作为预测手术治疗患者预后的生物标志物。Objective：To investigate the SIRT1 expressions in gastric cancer tissue and the potential association with clinicopathological characteristics and prognosis of the patients.Methods：The clinicopathological and survival information of the 142 cases who underwent radical gastrectomy at Nantong Cancer Hospital from January 1990 to December 1995,was collected to establish a combined database.The tissue microarray was made from the paraffin embed gastric cancer tissues and corresponding adjacent nontumoral gastric tissues from 142 resectable patients.Expressions of SIRT1 were evaluated by a semi-quantitative immunoreactivity scoring（IRS） procedure.The correlations between the expressions of the SIRT1 and clinicopathological as well as survival characteristics of patients were further analyzed.Results：Expressions of SIRT1 were significantly lower in cancer lesions than in adjacent noncancerous tissues.Low tumoral SIRT1 expression was associated with depth of invasion,presence of lymph node metastasis,high pTNM stage and poor differentiation,respectively.Importantly,reduced SIRT1 expressions in cancerous tissues were significantly correlated with shorter overall survival（OS） in patients（HR = 0.205,95%CI：0.124～0.339,P 〈 0.001）.Conclusion： SIRT1 might be a novel biomarker for evaluating progression and prognosis of resectable gastric cancer patients.

关 键 词：SIRT1 胃癌 预后 生物标志物 

分 类 号：Q786[生物学—分子生物学]